Goyen M, Debatin J F
Department of Diagnostic and Interventional Radiology, University Hospital Essen, Essen, Germany.
Eur Radiol. 2003 Nov;13 Suppl 3:N19-27. doi: 10.1007/s00330-003-0003-3.
Although limited in number, reports describing the use of Gd-BOPTA for 3D CE-MRA reveal that this agent is safe, well tolerated and effective for CE-MRA at doses up to 0.3 mmol/kg bodyweight. The use of Gd-BOPTA leads to additional diagnostically relevant information comparable to that attainable with conventional DSA and superior to that on non-enhanced MRA in most arterial territories. In studies in which Gd-BOPTA is compared at equal dose with other gadolinium-based MR contrast agents, Gd-BOPTA has consistently shown significantly better quantitative and qualitative performance. Thus, Gd-BOPTA can be considered to have a very favorable risk/benefit ratio for MRA. In summary, it is likely the documented superiority of Gd-BOPTA for MR angiography will lead to its broad usage for this indication wherever the agent becomes available.
尽管相关报告数量有限，但描述使用钆贝葡胺进行三维对比增强磁共振血管造影（3D CE-MRA）的报告显示，在高达0.3 mmol/kg体重的剂量下，该造影剂用于CE-MRA是安全的，耐受性良好且有效。使用钆贝葡胺可获得额外的与诊断相关的信息，这与传统数字减影血管造影（DSA）相当，并且在大多数动脉区域优于非增强MRA。在将钆贝葡胺与其他基于钆的磁共振造影剂以相同剂量进行比较的研究中，钆贝葡胺始终显示出明显更好的定量和定性性能。因此，钆贝葡胺可被认为在MRA方面具有非常有利的风险/效益比。总之，钆贝葡胺在磁共振血管造影方面已被证明的优势可能会使其在该造影剂可获得的任何地方广泛用于此适应症。
